Indian pharma co criticises Israeli firm over citizen petition

Posted on: Fri, 27 Nov 2009 03:12:00 EST


Symbols: TEVA, NAPHF
MUMBAI, Nov 26, 2009 (Asia In Focus via COMTEX) --
TEVA | Quote | Chart | News | PowerRating -- Indian drug maker NATCO
PHARMA LTD (BSE:524816) on Thursday said Israel-based TEVA
PHARMACEUTICAL INDUSTRIES has filed citizen petition with the
US regulator FDA in an effort to prolong its monopoly in
selling Copaxone, used in treating multiple sclerosis. "This
citizen petition is similar to another petition that Teva had
filed in 2008 which was rejected by US Food and Drug
Administration earlier this year," Natco Pharma said in a
filing with the Bombay Stock Exchange.

* "Filing of Citizen Petition is a common tactic employed by
the branded pharmaceutical companies in the US to delay generic
competition and Teva seems to have borrowed the manoeuvre from
the multinationals," Natco said.

* Natco said it would suitably respond to Teva's unfounded
claims while assuring safety and integrity of its drug
Glatiramer Acetate.

For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.

For full details on (NAPHF) NAPHF. (NAPHF) has Short Term PowerRatings at TradingMarkets. Details on (NAPHF) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.